Search This Blog

Saturday, January 11, 2020

New talc testing standards urged amid asbestos worries

An expert panel formed by the U.S. Food and Drug Administration has endorsed asbestos testing standards for cosmetics that reject long-held industry positions and reflect those of public health authorities and experts for thousands of plaintiffs who allege contaminated talc products caused their cancers.
The most significant recommendation from the panel of government experts is that mineral particles found in talc products small enough to be drawn into the lungs – even those the industry would not call asbestos – should be counted as potentially harmful.
Because both asbestos and look-alike minerals are suspected of causing “similar pathological outcomes, the distinction is irrelevant,” the expert panel said in a summary of its preliminary recommendations posted this week on the FDA’s website.
The panel also underscored the view of the World Health Organization and other public health authorities that there is no known safe level of asbestos exposure and called for talc powders and cosmetics to be tested with the most sensitive methods available.
The recommendations – which came from experts from eight government agencies, including the U.S. Geological Survey and National Institute for Occupational Safety and Health – are set to be considered Feb. 4 at the FDA campus in Silver Spring, Maryland. It will be the first FDA hearing focused on testing methods for asbestos in talc and cosmetics since 1971, according to the agency.
The panel’s assessment marks a sharp departure from that of previous advisers. In late 2018, at an FDA-sponsored meeting closed to the public, numerous experts with industry ties downplayed the potential hazard of talc contamination with asbestos lookalike minerals, according to a Reuters report in December. [LINK] The gathering and resulting reports drew criticism from other scientists, consumer advocates, a congressman and plaintiffs’ attorneys.
The agency declined to comment Friday on the substance of the new recommendations in advance of the meeting. In a statement, the FDA noted that its panel of government experts “worked independently and has not solicited recommendations from cosmetic manufacturers, industry groups or any other non-governmental groups.”
A spokesman for market leader Johnson & Johnson said the company looked “forward to a thorough review of the most effective and reliable ways to test for asbestos in cosmetic talc.”
In October, the FDA announced that it had found asbestos in a bottle of Johnson’s Baby Powder, prompting the recall of 33,000 bottles. The move marked the first time the company had recalled the iconic brand for possible asbestos contamination, as well as and the first time U.S. regulators had announced a finding of asbestos in the product.
After that, J&J hired outside labs to conduct a series of tests that it said found no asbestos in its talc.
J&J’s “test methods exceed industry standards, and just recently, 155 tests by third-party labs using state of the art methods, including those outlined by the FDA, show there is no asbestos in our talc,” said J&J spokesman Jake Sargent.

A spokeswoman for the Personal Care Products Council said the national cosmetics trade group had not had any interactions with the FDA about the upcoming meeting and declined to comment further.
The recommendations are an early step in U.S. regulators’ reconsideration of testing standards and safety parameters for the talc powders and cosmetics used by millions of people. Although talc and asbestos are similar minerals and are often found together in the ground, the FDA has never required manufacturers to test for the known carcinogen, allowing them to vet their products as they see fit.
FDA officials will consider the guidance in deciding whether to propose standardized testing methods and have not announced a timetable.
The panel’s recommendations could by themselves influence scientific practice and courtroom strategy, experts said.
Adam Zimmerman, a professor at Loyola Law School in Los Angeles, said the recommendations could be used in courtrooms to strengthen plaintiffs’ cases and were particularly valuable because they come from “experts looking out for public safety who don’t have any skin in the game.”
Mark Lanier, a plaintiffs’ lawyer for a group of women with ovarian cancer who won a $4.6 billion verdict against J&J, said he would use the recommendations in future trials. The FDA panel shot several of J&J’s defenses “out of the water,” he said.
Steven Compton, a director of a Duluth, Georgia-based lab that conducts tests for talc companies and has worked for plaintiffs, said the recommendations could provide guidance for scientists now operating in a vacuum, without recognized standards.
“It’s helpful for labs to understand what they should be counting — whether it’s for the courtroom or for a client in industry,” Compton said.
The FDA tests last year, which found asbestos in a number of widely sold cosmetics besides Johnson’s Baby Powder, renewed concerns among some members of Congress and consumer advocates about the risks of asbestos contamination in talc and the potential need for stricter safety standards to protect public health. Thousands of pending consumer lawsuits allege talc powders caused their ovarian cancer or mesothelioma, an incurable cancer of the lining of the lungs and other organs.
For decades, the cosmetic talc industry has largely been allowed to police itself, with little intervention from the FDA.
A 2018 Reuters report [link] showed that although J&J knew its raw talc and powders sometimes tested positive for asbestos from the 1970s into the early 2000s, the company did not report those findings to the FDA. The Dec. 3 Reuters report showed that, since the 1970s, the FDA downplayed health concerns about talc in powders and cosmetics and deferred again and again to manufacturers.
More recently, the agency has taken a tougher stance amid heightened scrutiny in Congress, a criminal investigation into J&J’s statements regarding the safety of its talc powders and jury verdicts against talc manufacturers.

Fitbit, Garmin, other wearable devices under U.S. scrutiny

The U.S. International Trade Commission says it will investigate wearable monitoring devices made by Fitbit (NYSE:FIT) and Garmin (NASDAQ:GRMN) following allegations of patent violations by rival Philips (NYSE:PHG).
Philips and Philips North America are calling for tariffs or an import ban and allege the other companies have infringed on Philips patents or misappropriated its intellectual property.
While the U.S. ITC agreed to launch a probe, it says it “has not yet made any decision on the merits of the case.”

Bayer cuts CRISPR stake to 7.2%

Bayer Global Investments (OTCPK:BAYRY) has cut its stake in CRISPR Therapeutics (NASDAQ:CRSP) to 7.2%, according to a filing.
It got there (from a previous stake of about 9.5%) by selling about 1.4M shares on a range of dates from Dec. 18 to Jan. 8, according to the filing.
As of its original filing date, Bayer beneficially owned 12.8% of CRISPR.

Friday, January 10, 2020

Walgreens Sees More Doctors Connected To Its Drugstores

Walgreens Boots Alliance sees the physician inside or attached to its drugstores as key to the company’s long-term survival as a community healthcare provider.
Though two partnerships Walgreens has to strengthen the drugstore chain’s relationships with physicians remain in testing stages, company executives say they are performing well and a future expansion could be around the corner. Walgreens provided an update on its physician partnerships Wednesday during its fiscal 2020 first quarter earnings call after inquiries from analysts who in the past have wondered when these partnerships are going to start contributing financial results to the company.
One relationship involves the big health insurer Humana and its Partners in Primary Care Centers inside two Walgreens stores in the Kansas City area and a third in Anderson, South Carolina. The Walgreens-Humana Partners in Primary Care relationship is a joint venture developing senior health clinics that treat patients covered by the insurer’s Medicare Advantage plans.
“It looks very good and is operating really well (and) the relationship between the pharmacist and doctors is really close,” Walgreens co-chief operating officer Alex Gourlay told analysts Wednesday on the company’s fiscal first quarter earnings call. “We continue to feel really good about that very small, but important, test joint venture.”
The effort is designed in part to keep people out of the more expensive hospital setting and make sure Medicare patients have their care more closely monitored by Walgreens pharmacists and physicians in Humana’s health plan networks. The two companies think they can do a better job of reaching patients who visit Walgreens retail locations and making sure they get better care upfront before they get sick.
The other partnership Walgreens has with physicians involves the Chicago-based startup VillageMD, which operates primary care clinics that have contracts with physicians. The 2,500-square-foot clinics are being located next to five Walgreens stores that will be open in the Houston area by the end of February and are called “Village Medical at Walgreens.”
“We are very, very pleased with how that’s operating already,” Gourlay said of VillageMD, which Walgreens has invested a “small” undisclosed stake in. “We see that partnership of the doctor and the pharmacist as … fundamental to the future of community health care delivery going forward and core to our model.”
Walgreens developing partnerships with doctor-staffed clinics is in contrast to rival CVS Health’s primary care services via its MinuteClinics, which are staffed by nurse practitioners. CVS is also rolling out a new “HealthHub” format that will be in 1,500 stores by the end of 2021.

Kadmon to present KD025 data at conference

Kadmon Holdings (NYSE:KDMN) is up 2.2% after hours following the acceptance of a late-breaking abstract of its trial of KD025 in chronic graft-versus-host disease for the 2020 Transplantation & Cellular Therapy Meetings.
That’s set for Feb. 19-23 in Orlando, Fla.
The expanded data set from the ROCKstar trial will include repsonse rate across key subgroups and initial safety data.
In November, Kadmon had said that KD025 met the primary endpoint at the interim analysis.

New Coronavirus May Be Cause of Viral Pneumonia Outbreak in China

A new type of coronavirus may be responsible for dozens of viral pneumonia illnesses in China, according to state broadcaster CCTV.
As of Sunday, 59 people in the central Chinese city of Wuhan were being treated for the respiratory illness, and seven were in critical condition, according to health officials.
As of Wednesday evening, the new coronavirus had been detected in 15 of those cases, CCTV reported. There was no immediate confirmation by Chinese health officials, the Associated Press reported.
The new coronavirus is different than previously identified ones, according to CCTV. Some coronaviruses can cause colds, while others can trigger severe respiratory diseases such as SARS and MERS, the AP reported.

Alcohol-Fueled Deaths Double in U.S. Over Past 20 Years

The number of Americans dying from alcohol abuse each year has doubled since 1999, a new study reveals.
Between 1999 and 2017, alcohol-related deaths jumped from nearly 36,000 a year to almost 73,000. That’s about 1 million deaths lost to booze over less than two decades, with white women experiencing the greatest annual increases.
“Those deaths are associated with despair — loss of hope, loss of employment and opportunities for employment, increase in stress — leading to substance abuse and alcohol abuse,” said lead researcher Aaron White. He’s a neuroscientist with the U.S. National Institute on Alcohol Abuse and Alcoholism.
Rising deaths from opioid overdoses and suicide have garnered more attention than alcohol in recent years, White said.
“We sort of forget about alcohol because it’s been around for so long, but it has its fingerprints all over the increase in the deaths involved in deaths of despair,” he said.
At least 1 in 5 overdose deaths involves excessive drinking, White noted.
“We think what these data show is what we as an institute have known for quite some time, which is that alcohol causes a considerable amount of harm in our society,” he said.
For the study, White’s team reviewed death certificate data from the U.S. National Center for Health Statistics. They found that in 2017, alcohol abuse accounted for 2.6% of the nearly 3 million deaths in the United States.
Among these deaths, nearly 50% were from liver disease or overdoses of liquor alone or combined with other drugs, the researchers found.
Alcohol-related deaths were highest among men, people ages 45 to 74, and among Native Americans and Native Alaskans.
Deaths, however, have been increasing among all groups, especially women, White said.
“Women are at greater risk than men at comparable levels of alcohol exposure for alcohol-related cardiovascular diseases, certain cancers, alcohol-related liver disease and acute liver failure due to excessive drinking,” the study authors wrote.
That may be due to their physiology. “Because women reach higher blood alcohol levels than men of comparable weights after consuming the same amount of alcohol, their body tissues are exposed to more alcohol and acetaldehyde, a toxic metabolite of alcohol, after each drink,” the authors added.
Why alcohol-fueled deaths are rising overall isn’t really known, White said.
“I wish I had a good answer, but I just don’t,” White said.
He added that until the root causes of these deaths are known, the only way to help people is to increase resources for addiction treatment.
Dr. J.C. Garbutt is a professor of psychiatry at the University of North Carolina School of Medicine’s Bowles Center for Alcohol Studies. He, too, said the study highlights the nation’s worrisome spike in deaths of despair.
The reasons for the despair are complex, “but are likely relate to a loss of job security, financial collapse, community fragmentation and isolation and other social problems precipitated by our changing world economy and changing culture,” said Garbutt, who wasn’t part of the study.
Alcohol provides a temporary coping mechanism. It temporarily reduces anxiety and tension, sometimes elevating mood, reducing pain and sometimes leading to brief respites from one’s worries, he said.
But alcohol also leads to increased anxiety, stress sensitivity, depression, sleep problems and irritability, Garbutt said. “Alcohol, being the sneaky drug that it is, says to the brain, ‘The best way to calm this down is drink more.’ Thus, a vicious cycle begins,” he explained.
The paper highlights the need to get more information to the public about alcohol’s harms, he said.
“Historically, the message about alcohol consumption has been very confusing — drinking red wine is good for you, a little alcohol a day will make you live longer,” Garbutt said. But over the past 10 years, “we have become aware that for health, it is probably better to drink as little as one can.”
People need to know that if they cut down or even stop drinking, it is likely that they will feel better, he said.
The report was published Jan. 8 in the journal Alcoholism: Clinical & Experimental Research.
More information
For more on drinking and health, see the U.S. National Institute on Alcohol Abuse and Alcoholism.
SOURCES: Aaron White, Ph.D., U.S. National Institute on Alcohol Abuse University of North Carolina School of Medicine, Bowles Center for Alcohol Studies, Chapel Hill; Jan. 8, 2020, Alcoholism: Clinical & Experimental Research